Search
# Popular search #
0%
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions
Gan & Lee Pharmaceuticals' Insulin Aspart Receives NPRA Approval in Malaysia
Global Diabetes Experts Visited Gan & Lee Pharmaceuticals’ R&D and Manufacturing Facilities
Multinational Diabetes Academic Conference 2025 Opens in Beijing, Gathering Global Experts to Explore New Trends in Prevention and Treatment
Conference Preview: Gan & Lee Pharmaceuticals to Attend the American Diabetes Association’s 85th Scientific Sessions
Gan & Lee CEO Du Kai and Brazilian Health Minister Convene to Forge New Frontiers in Diabetes Prevention and Treatment
To be a world-class pharmaceutical company with focus on global business development
Registered in 23 countries
Products launched in 19 countries
Clinical trials conducted in 10 countries
Registered in 23 countries
Products launched in 19 countries
Clinical trials conducted in 10 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.
